Clinical trials: Single Women
Type 2 Diabetes
Acute Effect of Tai Chi Versus Moderate-Intensity Combined Exercise on Cardiovascular, Metabolic, and Cardiac Autonomic Control Parameters in Older Men and Women With Type 2 Diabetes Mellitus
Type 2 diabetes mellitus (T2DM) in the elderly population is associated with compromised cardiovascular and metabolic functions, thereby necessitating the implementation of safe exercise interventions.
- Trial name
- NCT07113444
- Testing
- Tai Chi, Moderate-Intensity Combined Exercise (MICE), Control ( No Exercise )
- Volunteers
- 24 people
- Sponsor
- Universidade Estadual Paulista Júlio de Mesquita Filho
Chronic Kidney Diseases, Calciphylaxis
Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis
Treatment for Calciphylaxis Patients with Human Amniotic-derived Mesenchymal Stem Cells
- Conditions
- Chronic Kidney Diseases, Calciphylaxis, Calcific Uremic Arteriolopathy, Treatment
- Trial name
- NCT04592640
- Testing
- Human amniotic-derived mesenchymal stem cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Ovarian Cancer
Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients
ICON 9 will assess the efficacy, safety and tolerability of maintenance olaparib in combination with cediranib compared to maintenance olaparib alone following a response to platinum-based chemotherapy in women with relapsed…
- Trial name
- ICON9 (NCT03278717)
- Testing
- Olaparib, Cediranib
- Where
- 54 sites in Australia, Canada and 2 more
- Volunteers
- 330 people
- Sponsor
- University College, London
Healthy Volunteers
A Pharmacokinetic Study to Characterize JNJ-39393406 in the Cerebrospinal Fluid of Healthy Volunteers
The purpose of this study is to investigate the concentration of JNJ-39393406 achieved in the blood and cerebrospinal fluid of healthy adult volunteers following administration of a single dose of JNJ-39393406.
- Trial name
- NCT01556217
- Testing
- JNJ-39393406
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Healthy
Relative Bioavailability of a Linagliptin+Metformin Fixed Dose Combination Tablet Administered With and Without Food to Healthy Male and Female Subjects
Study to investigate the effect of food on the relative bioavailability of a 2.5 mg linagliptin+1000 mg metformin fixed dose combination (FDC) tablet
- Trial name
- NCT02223026
- Testing
- Linagliptin/metformin FDC, high-fat, high caloric meal
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Ovarian Cancer, Fallopian Tube Cancer
A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
Ovarian cancer is the leading cause of gynecologic cancer deaths, and the fifth most common cause of cancer deaths in women. While approximately 75% of patients with epithelial ovarian cancer will respond to first-line…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT01610206
- Testing
- Gemcitabine, pazopanib
- Where
- 8 sites in United States
- Volunteers
- 148 people
- Sponsor
- Linda R Duska
Anti-Glomerular Basement Membrane Disease
A Clinical Trial With KJ103 in Anti-GBM Disease
An open-label, single-arm Phase II study to evaluate the preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of KJ103 in patients with anti-GBM disease.
- Trial name
- NCT06607016
- Testing
- KJ103 for Injection, Cyclophosphamide, Glucocorticoids
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai Bao Pharmaceuticals Co., Ltd.
Urinary Bladder Neoplasms, Carcinoma, Transitional Cell
Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study
This open-label, randomised, multicentre, phase 2 study (OHAI-NMIBC-01) compares toripalimab plus sequential intravesical gemcitabine followed by mitomycin C (GEM→MMC) with toripalimab alone in adults with BCG-unresponsive or…
- Conditions
- Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Carcinoma in Situ of Bladder, Non-Muscle-Invasive Bladder Cancer
- Trial name
- OHAI-NMIBC-01 (NCT07189793)
- Testing
- Toripalimab, Gemcitabine (GEM), Mitomycin C (MMC)
- Where
- China
- Volunteers
- 106 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Ovarian Cancer
Fluzoparib Neoadjuvant Therapy for Ovarian Cancer
This study is an interventional, single-arm, open-label clinical trial. To evaluate the safety and efficacy of Fluzoparib as neoadjuvant therapy in patients with FIGO stage III and IV , BRCA mutations or HRD positive epithelial…
- Trial name
- NCT06541314
- Testing
- Fluzoparib
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Qilu Hospital of Shandong University
Urinary Tract Infections, Urinary Retention Postoperative
Urinary Track Infection Prevention After Urogynecological Surgery
This study is randomized double-blinded placebo-controlled trial to access oral Methenamine Hippurate (MH) in combination with cranberry capsules is superior to cranberry capsules alone in prevention of UTI in patients with…
- Conditions
- Urinary Tract Infections, Urinary Retention Postoperative, Pelvic Organ Prolapse
- Trial name
- NCT03818321
- Testing
- Methenamine Hippurate 1 g tablet
- Where
- United States
- Volunteers
- 185 people
- Sponsor
- TriHealth Inc.
Bladder Cancer, Urothelial Carcinoma
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
This study aims to demonstrate that home instillation of UGN-102 is a feasible alternative to instillation in a clinical setting, which might mitigate patient challenges (logistical, expense, and comfort) when receiving treatment…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
- Trial name
- NCT05136898
- Testing
- UGN-102
- Where
- 5 sites in United States
- Volunteers
- 8 people
- Sponsor
- UroGen Pharma Ltd.
Dyslipidaemia
Study of the Electrocardiographic Effects of TA-8995
A study in healthy males and females to see if a high single dose of TA-8995 has an effect on the ECG QTcF interval.
- Trial name
- NCT02241759
- Testing
- TA-8995, Moxifloxacin
- Where
- United Kingdom
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Xention Ltd
Vulvovaginal Candidiasis
MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis
The primary objective of the study is to evaluate the rate of therapeutic cure of the combination treatment of MGCD290 and fluconazole as compared to that of fluconazole alone at Test of Cure Visit for patients with moderate to…
- Trial name
- NCT01497223
- Testing
- MGCD290
- Where
- 19 sites in United States
- Volunteers
- 220 people
- Sponsor
- MethylGene Inc.
Renal Insufficiency
The Pharmacokinetics of Gefapixant (MK-7264) in Participants With Renal Insufficiency (MK-7264-026)
This trial aims to evaluate the plasma pharmacokinetics of gefapixant (MK-7264) administered to participants with varying degrees of renal insufficiency (RI) compared to healthy matched controls; and to investigate the extent of…
- Trial name
- NCT03108924
- Testing
- Gefapixant
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women
The purpose of this study is to assess the effect of cytochrome P450 isoenzyme 2D6 (CYP2D6) inhibition by quinidine on the pharmacokinetic (PK) parameters of a single dose SEP-380135 in healthy adult participants.
- Trial name
- NCT07305779
- Testing
- SEP-380135, Quinidine Gluconate
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Ovarian Cancer, Stage III Ovarian Cancer
Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer
The goal of this clinical trial is to test alternative dosing of niraparib in patients with newly diagnosed high-grade, advanced stage ovarian cancer.
- Conditions
- Ovarian Cancer, Stage III Ovarian Cancer, Stage IV Ovarian Cancer, High Grade Ovarian Serous Adenocarcinoma
- Trial name
- NCT05961124
- Testing
- Niraparib
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Sunnybrook Health Sciences Centre
Healthy Volunteers
First-in-human: Single Ascending Dose, Food Effect, Drug-drug Interaction, Multiple Ascending Dose, Proof of Pharmacology
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending oral doses of ASP6282 in healthy male and female subjects.
- Trial name
- NCT02420782
- Testing
- ASP6282, Itraconazole, Pilocarpine
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Renal Cell Carcinoma (RCC), Metastatic Renal Cell Carcinoma (mRCC)
PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk
This phase 2 trial aims to test the feasibility and efficiency of PET/CT-directed treatment interruption strategy in metastatic renal cell carcinoma patients with IMDC favorable/intermediate risk who achieve complete (CMR) or…
- Trial name
- Perfumer (NCT07175480)
- Testing
- Intermittent PD-1/PD-L1 ICI + VEGFR-TKI
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jinling Hospital, China
Healthy
A Study in Healthy People to Compare 2 Different Formulations of Nerandomilast Tablets When Taken With or Without Food
The main objective of this trial is to investigate two different formulations of nerandomilast and the effect of food on the pharmacokinetics of the new formulation following oral administration.
- Trial name
- NCT06624072
- Testing
- Nerandomilast 18 mg - adult formulation, Nerandomilast 1 mg - paediatric formulation
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC)
Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT
The goal of this clinical trial is to evaluate whether Finerenone and Empagliflozin, either alone or in combination, can delay the progression of renal function decline in patients at high risk for chronic kidney disease (CKD)…
- Conditions
- Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Nephrectomy, Chronic Kidney Disease(CKD)
- Trial name
- EmFin-Nx (NCT06818305)
- Testing
- Finerenone (BAY 94-8862), Empagliflozin 10 mg
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Jinling Hospital, China
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.